NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
1-{2-[4-(2-phenyl-1-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}but-1-en-1-yl)phenoxy]ethyl}pyrrolidine
|
|
|
IUPAC Traditional name
|
1-{2-[4-(2-phenyl-1-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}but-1-en-1-yl)phenoxy]ethyl}pyrrolidine
|
|
|
Synonyms
|
1,1′-[(2-Phenyl-1-buten-1-ylidene)bis(4,1-phenyleneoxy-2,1-ethanediyl)]bis-pyrrolidine
|
Ridaifen-B
|
|
|
CAS Number
|
|
MDL Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
Molar Refractivity
|
167.9951 cm3
|
Polarizability
|
61.921078 Å3
|
Polar Surface Area
|
24.94 Å2
|
Rotatable Bonds
|
12
|
Lipinski's Rule of Five
|
false
|
H Acceptors
|
4
|
H Donor
|
0
|
LogD (pH = 5.5)
|
0.6703884
|
LogD (pH = 7.4)
|
3.8996856
|
Log P
|
7.0237904
|
DETAILS
DETAILS
Sigma Aldrich
Sigma Aldrich -
R5030
|
Biochem/physiol Actions Ridaifen-B (RID-B) is a novel tamoxifen (TAM) analog that significantly augments apoptosis-inducing effect of TAM in estrogen receptor (ER)-negatives cells. Ridaifen-B induces mitochondria-involved apoptosis in Jurkat cells, as evidenced by chromatin-condensed cells as well as downstream activation of caspases (caspase-3, -8 and -9) in a dose- and time-dependent manner. At 4 hours of incubation, IC50 for RID-B is 4 muM (30 muM for TAM). And at prolonged treatment of 48 hours, IC50 for RID-B is 0.1 muM.1 In a related report2 on the global anti-tumor activity, RID-B strongly inhibits 39 human cancer cells (JFCR 39), both ER-+ or ER-- at concentrations of equal or less than 1muM (e.g., at 0.38muM for SF-539 [central nervous system], at 0.58muM for HT-29 [colon], at 0.20muM for DMS114 [lung], at 0.21muM for LOX-IMVI [melanoma], and at 0.23muM for MKN74 [stomach]. The binding protein of RID-B that exerts the apoptosis events is currently under investigation. |
PATENTS
PATENTS
PubChem Patent
Google Patent